company background image
CPH

Creso PharmaASX:CPH Stock Report

Market Cap

AU$138.2m

7D

4.5%

1Y

296.6%

Updated

19 Oct, 2021

Data

Company Financials
CPH fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

CPH Overview

Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, North America, and the Asia Pacific.

Price History & Performance

Summary of all time highs, changes and price drops for Creso Pharma
Historical stock prices
Current Share PriceAU$0.12
52 Week HighAU$0.024
52 Week LowAU$0.47
Beta3.39
1 Month Change0%
3 Month Change-11.54%
1 Year Change296.55%
3 Year Change-75.53%
5 Year Change-63.49%
Change since IPO-55.77%

Recent News & Updates

Shareholder Returns

CPHAU PharmaceuticalsAU Market
7D4.5%1.8%1.7%
1Y296.6%5.8%20.2%

Return vs Industry: CPH exceeded the Australian Pharmaceuticals industry which returned 4.9% over the past year.

Return vs Market: CPH exceeded the Australian Market which returned 20.3% over the past year.

Price Volatility

Is CPH's price volatile compared to industry and market?
CPH volatility
CPH Beta3.39
Industry Beta1.3
Market Beta1

Stable Share Price: CPH is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: CPH's weekly volatility has decreased from 21% to 8% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015n/an/ahttps://www.cresopharma.com

Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, North America, and the Asia Pacific. The company develops and commercializes therapeutic products; and cultivates and harvests cannabis plants, as well as supplies dried cannabis plant retail products. Its products include anibidiol, a complementary feed product for companion animals; cannaQIX, a nutraceutical product containing hemp oil extract, and vitamins and zinc that reduces stress and supports psychological and nervous functions in humans; and topical and skin care products, which include cannaDOL, a CBD-based topical gel associated with a mixture of cooling and warming essential oils.

Creso Pharma Fundamentals Summary

How do Creso Pharma's earnings and revenue compare to its market cap?
CPH fundamental statistics
Market CapAU$138.18m
Earnings (TTM)-AU$32.34m
Revenue (TTM)AU$4.03m

34.3x

P/S Ratio

-4.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CPH income statement (TTM)
RevenueAU$4.03m
Cost of RevenueAU$7.28m
Gross Profit-AU$3.26m
ExpensesAU$29.08m
Earnings-AU$32.34m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.027
Gross Margin-80.93%
Net Profit Margin-803.27%
Debt/Equity Ratio0.0%

How did CPH perform over the long term?

See historical performance and comparison

Valuation

Is Creso Pharma undervalued compared to its fair value and its price relative to the market?

5.16x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CPH's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CPH's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CPH is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.

PE vs Market: CPH is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CPH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CPH is overvalued based on its PB Ratio (5.2x) compared to the AU Pharmaceuticals industry average (3.5x).


Future Growth

How is Creso Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

67.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Creso Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Creso Pharma performed over the past 5 years?

-29.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CPH is currently unprofitable.

Growing Profit Margin: CPH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CPH is unprofitable, and losses have increased over the past 5 years at a rate of 29.6% per year.

Accelerating Growth: Unable to compare CPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).


Return on Equity

High ROE: CPH has a negative Return on Equity (-120.75%), as it is currently unprofitable.


Financial Health

How is Creso Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: CPH's short term assets (A$16.6M) exceed its short term liabilities (A$1.3M).

Long Term Liabilities: CPH has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: CPH is debt free.

Reducing Debt: CPH had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CPH has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CPH has less than a year of cash runway if free cash flow continues to reduce at historical rates of 25% each year


Dividend

What is Creso Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CPH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CPH's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Creso Pharma has no CEO, or we have no data on them.


Leadership Team

Experienced Management: CPH's management team is considered experienced (3 years average tenure).


Board Members

Experienced Board: CPH's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 74.5%.


Top Shareholders

Company Information

Creso Pharma Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Creso Pharma Limited
  • Ticker: CPH
  • Exchange: ASX
  • Founded: 2015
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$138.180m
  • Shares outstanding: 1.20b
  • Website: https://www.cresopharma.com

Location

  • Creso Pharma Limited
  • 145 Stirling Highway
  • Suite 5 CPC
  • Nedlands
  • Western Australia
  • 6009
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/19 15:54
End of Day Share Price2021/10/19 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.